Novavax Vaccine Trial Shows 90% Effectiveness Against COVID-19

The Novavax Covid-19 vaccine was 90 percent effective in the last phase of its trial in the United States and Mexico and proved able to treat variants of the virus of concern, opening the way for approval of another injection to control the epidemic.

Company based in Maryland – which – after 33 years, a product has not yet been approved – it said its vaccine offers 100 per cent protection against moderate and severe Covid-19. All cases of Covid-19 in the vaccinated group were mild.

The two-dose vaccine showed 93 percent efficacy against variants of concern and emerging variants of interest, which account for the vast majority of cases. It was 91 percent effective for people in high-risk groups, such as those over 65 and those with underlying conditions.

Novavax CEO Stanley Erk said the vaccine maker is now “one step closer” to “meeting critical and ongoing global public health needs for additional vaccines for Covid-19.”

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and bring this vaccine, built on a well-understood and proven platform, to a world still in dire need of vaccines,” he said.

The company uses a traditional method for its vaccine, but it grows its protein into the moth’s cells, expands it rapidly, and then encapsulates it into nanoparticles. This antigen, which teaches the body to recognize the spike protein, is boosted by a proprietary adjuvant.

Data from the trial of nearly 30,000 participants in the United States and Mexico are similar to previously published results from the Novavax trials in the United Kingdom and South Africa. Then I found that a file The vaccine was 96 percent effective Against the original strain of Sars CoV-2.

But the vaccine was significantly less effective against the beta variant that first appeared in South Africa. Last week, Novavax said that a vaccine designed for this type elicited immune responses in… Animal and human studies Against beta and other strains, paving the way for its use as a reinforcer.

While trial data from outside the US was released in March, the company has yet to finalize regulatory filings and has struggled with production issues that have delayed its schedules. On Monday, it said it needed to meet chemistry, manufacturing and oversight requirements.

Novavax received $1.6 billion from Operation Warp Speed, which helped fund the production of 100 million doses. The UK government has agreed to buy 60 million doses, as part of a deal where Novavax will produce a key component of the vaccine in Stockton-on-Tees.

The vaccine also proved safe in the US and Mexico trial, with few serious adverse events, and is evenly balanced between participants who took the vaccine and those who took the placebo. The most common side effects were fatigue, headache, and muscle aches, as with many vaccinations.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button